find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
60
Clinical Trials
Lymphoma
NA
Accepting Patients
nct/study# NA / 2021-0513
Outcomes Of Patients With Aggressive B-Cell Non-Hodgkin S Lymphoma Who Undergo Hematopoietic Cell Transplantation After CAR T-Cell Therapy
Learn More
Lymphoma
Phase II
Accepting Patients
nct/study# NCT03113500 / COH-17058
A Phase 2 Study Of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, And Prednisone (CHEP-BV) Followed By BV Consolidation In Patients With CD30-Positive Peripheral T-Cell Lymphomas
Learn More
Lymphoma
Phase II
Accepting Patients
nct/study# NCT03712202 / COH18157
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin And Nivolumab Incorporated And Radiation Free Management Of Early Stage Classical Hodgkin Lymphoma (Chl)
Learn More
Lymphoma
Phase I
Accepting Patients
nct/study# NCT03952078 / CPI-818-001
A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, An Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, In Subjects With Relapsed/Refractory T-Cell And Follicular B-Cell Non-Hodgkin Lymphoma
Learn More
Lymphoma
Phase I
Accepting Patients
nct/study# NCT02732275 / DS3201-A-J101
A Phase 1 Multiple Ascending Dose Study Of DS-3201b In Subjects With Lymphomas
Learn More
Lymphoma
Phase I
Accepting Patients
nct/study# NCT02616965 / HM-085
A Phase I Trial Assessing The Feasibility Of Romidepsin Combined With Brentuximab Vedotin For Patients With Requiring Systemic Therapy For Cutaneous T-Cell Lymphoma
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.